SCHEMBL7014968

SCHEMBL7014968

Cc1ccc([C@H](C)NC(=O)[C@H](C)NC(=O)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 3/20 0.61
SMN1; SMN2 Q16637 5/20 0.60
LMNA P02545 4/20 0.57
ALDH1A1 P00352 4/20 0.57
MMP9 P14780 1/20 0.55
MMP8 P22894 1/20 0.55
NPC1 O15118 2/20 0.52
TP53 P04637 1/20 0.50
ROCK2 O75116 1/20 0.48
RPS6KA5 O75582 1/20 0.48
MAP4K4 O95819 1/20 0.48
CDK1 P06493 1/20 0.48
CSF1R P07333 1/20 0.48
PRKACA P17612 1/20 0.48
FLT1 P17948 1/20 0.48
RPS6KB1 P23443 1/20 0.48
CDK2 P24941 1/20 0.48
MAPK1 P28482 1/20 0.48
AKT1 P31749 1/20 0.48
FLT4 P35916 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28651689 0.89 SMN1; SMN2 (0.73) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL9318785 0.89 SMN1; SMN2 (0.73) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL7015587 0.86 SMN1; SMN2 (0.57) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL7017250 0.83 SMN1; SMN2 (0.55) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL13947536 0.83 ALDH1A1 (0.73) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL7021535 0.81 GPR139 (0.65) GPR139SMN1; SMN2MMP9MMP8
SCHEMBL7010951 0.80 MMP9 (0.50) GPR139MMP9MMP8MEN1KMT2A
SCHEMBL5968858 0.79 ALDH1A1 (0.77) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL751213 0.79 ALDH1A1 (0.77) GPR139SMN1; SMN2LMNAALDH1A1NPC1
SCHEMBL1101522 0.79 ALDH1A1 (0.77) GPR139SMN1; SMN2LMNAALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670447-B2 An 3-acyl-4-substituted-oxazolidin-2,5-dione that readily reacts with nucleophilic reagents such as free amino acids; use in peptide synthesis for example MITSUI CHEMICALS, INC. (JP) 2003-12-30 US disclosed
EP-1298127-A1 AMINO ACID-N-CARBOXY ANHYDRIDES HVAING SUBSTITUENT AT NITROGEN Mitsui Chemicals, Inc. (JP) 2003-04-02 EP disclosed
US-20020173664-A1 Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen MITSUI CHEMICALS, INC. (JP) 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173664-A1 Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen DNPEP, HDGF, ANPEP GPR139 797/4885SMN1; SMN2 3873/4885LMNA 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.